News

Cobimetinib plus Zelboraf reduced the risk of disease worsening by half compared to Zelboraf alone Phase III coBRIM study results will be presented today during the Presidential Symposium at the European Society of Medical Oncology (ESMO) 2014 Congress and published in the New England Journal of Medicine Roche has submitted an EU marketing authorisation application […]

Final data from Phase III CLEOPATRA study showed people with previously untreated HER2-positive metastatic breast cancer who received Perjeta, Herceptin and docetaxel chemotherapy lived a median of 56.5 months compared to 40.8 months for people who received Herceptin and chemotherapy1 Median overall survival of almost five years is the longest observed to date in people […]

New Amersham™ WB system for reproducible and quantitative protein analysis The first fully-integrated system based on the traditional Western blotting technique which achieves reliably consistent results with fewer repeats and control experiments Chalfont St Giles, UK — 23 September 2014 – GE Healthcare Life Sciences (NYSE:GE) today launched Amersham WB system, a fully integrated system […]

WAUKESHA, Wis. — September 22, 2014 — GE Healthcare today announced U.S. FDA 510(k) clearance of its Discovery* IQ PET/CT system, enabling both outstanding image quality and intelligent quantitation to help physicians deliver the best possible patient outcomes. Physicians not only want the ability to detect smaller lesions, but also the ability to determine whether […]

Data to be Presented at European Society for Medical Oncology Congress in Madrid FOSTER CITY, Calif.–(BUSINESS WIRE)–Sep. 17, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 (LOXL2), in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. In the study, […]

Presentations will include Results from the Phase III coBRIM study of Roche’s investigational MEK inhibitor cobimetinib plus Zelboraf compared to Zelboraf alone, potentially paving the way for a new standard of care Final survival data from the Phase III CLEOPATRA study of the combination of Perjeta, Herceptin and chemotherapy, further confirming the potential of this […]

GE Launches new Voluson E10 featuring world’s first curved electronic 4D probe and next generation of HDlive Barcelona, Spain September 15, 2014 – GE Healthcare announced today commercial availability in the U.S, Europe and Japan for its new Voluson E10 ultrasound system featuring the world’s first curved matrix electronic 4D probe designed specifically for OB/GYN […]

Multidisciplinary solutions to help integrate planning and improve quantitation and efficiency in radiation oncology SAN FRANCISCO, CALIFORNIA — September 15, 2014 — GE Healthcare, a division of General Electric Company (NYSE: GE), is highlighting advanced imaging technologies and software capabilities at the 56th Annual American Society for Radiation Oncology (ASTRO) Meeting in San Francisco, California. […]

Satisfies Unmet Customer Need for Automated Performance Reports ABBOTT PARK, Ill., September 11, 2014 – Abbott has introduced worldwide a new, automated performance monitoring subscription, mView, for its widely used m2000 molecular diagnostics system. mView is designed to automate data analysis and help laboratories reduce the number of manually generated reports. A survey of molecular […]

September 8, 2014 – MIAMI–West Kendall Baptist Hospital in Miami has announced the purchase and installation of a highly advanced computed tomography (CT) scanner following a six-month evaluation at the hospital — the clinical trial of the equipment in the United States. With the convergence of whole-organ coverage, image quality, and speed found in GE […]